短期糖皮质激素桥接治疗减少早期类风湿关节炎患者慢性NSAID和镇痛药使用
该研究为CareRA随机对照试验的亚分析,纳入预后良好的早期类风湿关节炎患者,比较甲氨蝶呤联合短期口服糖皮质激素桥接方案(COBRA Slim)与甲氨蝶呤单药(TSU)对镇痛药使用的影响。结果显示,COBRA Slim组慢性使用NSAID和镇痛药的患者比例显著低于TSU组(21% vs 53%),慢性使用NSAID的比例也显著更低(14% vs 40%)。
要点
- 预后良好的早期RA患者中,COBRA Slim组慢性使用NSAID/镇痛药比例(21%)显著低于TSU组(53%)。
- COBRA Slim组慢性使用NSAID比例(14%)显著低于TSU组(40%)(p<0.01)。
- 研究期间任意时间使用NSAID/镇痛药的患者比例两组差异显著(p<0.01)。
核心结论
- 在预后良好的早期类风湿关节炎患者中,初始口服糖皮质激素桥接治疗可降低慢性NSAID和镇痛药的使用。
研究设计与样本
- CareRA随机对照试验的亚分析,纳入病程≤1年、预后良好(无骨侵蚀、RF和抗CCP抗体阴性或低疾病活动度)的早期RA患者,随机分为COBRA Slim组(MTX 15mg联合递减激素方案,43例)和TSU组(MTX无口服激素,47例),随访2年。
- 记录镇痛药使用频率、起止日期和适应症,慢性摄入定义为因肌肉骨骼疼痛连续使用NSAID、对乙酰氨基酚、阿片类药物(包括曲马多)或抗抑郁药≥90天。
- 采用χ2检验和方差分析,并用Holm校正进行多重比较。
主要发现
- 研究开始时,COBRA Slim组33/43(77%)和TSU组32/47(68%)患者曾使用镇痛药(p=0.5)。
- 试验期间,COBRA Slim组26/43(60%)患者使用67次NSAID和镇痛药治疗MSK疼痛,其中9/43(21%)每日慢性使用;TSU组43/47(92%)患者使用107次,其中25/47(53%)每日慢性使用。
- 研究期间任意时间使用NSAID和镇痛药的患者总数两组差异显著(p<0.01),慢性使用患者数差异显著(p=0.01)。
- 每日慢性使用NSAID的患者数COBRA Slim组6/43(14%)显著低于TSU组19/47(40%)(p<0.01)。
关键数值与推荐
- 慢性摄入定义:因肌肉骨骼疼痛连续使用NSAID、对乙酰氨基酚、阿片类药物(包括曲马多)或抗抑郁药≥90天。
- COBRA Slim方案:MTX 15mg联合递减糖皮质激素方案;TSU方案:MTX无口服激素。
临床怎么用
- 对于预后良好的早期RA患者,初始口服糖皮质激素桥接治疗可能减少长期NSAID和镇痛药的使用。
- 临床决策时可考虑短期激素桥接作为减少慢性镇痛药依赖的策略之一。
局限性
- 本研究为CareRA试验的亚分析,样本量较小(COBRA Slim组43例,TSU组47例)。
- 仅纳入预后良好的早期RA患者,结果可能不适用于其他RA人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore non-steroidal anti-inflammatory drug (NSAID) and analgesic use in early rheumatoid arthritis (eRA) patients with a favourable risk profile initiating methotrexate (MTX) with or without glucocorticoid (GC) bridging. METHODS: Patients with eRA (≤1 year) and favourable risk profile (no erosions, negative rheumatoid factor and anticitrullinated protein antibodiesor low disease activity) in the 2-year CareRA trial were randomised to MTX 15 mg with a step-down GC scheme (COBRA Slim), or MTX without oral GCs, Tight-Step-Up (TSU). Used analgesics were recorded, including frequency, start/end date and indication. Chronic intake (≥90 consecutive days in trial) of NSAIDs, acetaminophen, opioids including tramadol and antidepressants for the indication of musculoskeletal (MSK) pain was considered. Treatments were compared using χ2 and analysis of variance with Holm's correction for multiple testing. RESULTS: In total, 43 patients were randomised to COBRA Slim and 47 to TSU. At study inclusion, 33/43 (77%) of patients in the COBRA Slim and 32/47 (68%) in the TSU arm had been using analgesics (p=0.5). During the trial, 67 NSAID and analgesics were used for MSK pain in 26/43 (60%) COBRA Slim patients of which 9/43 (21%) daily chronically (DC), while 107 NSAID and analgesics were used in 43/47 (92%) TSU patients, of which 25/47 (53%) DC. The total number of patients on NSAID and analgesics at any time during the study (p<0.01) and chronically (p=0.01) was significantly different between treatment arms. Number of patients on DC NSAIDs was also significantly different (p<0.01) between COBRA Slim 6/43 (14%) and TSU 19/47 (40%). CONCLUSION: In eRA patients considered to have a favourable prognosis, initial oral GC bridging resulted in lower chronic NSAID and analgesic use. TRIAL REGISTRATION NUMBER: NCT01172639.
引用
- Pazmino S, Boonen A, De Cock D, et al. Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised controlled trial. RMD Open. 2021. PMID: 34031262. doi:10.1136/rmdopen-2021-001615
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。